Research & Development: Page 14
-
Getty Images
Investors put $400M into biotech licensing obesity drugs from China
The biotech, tentatively named Hercules CM Newco, has rights to three incretin drugs discovered by Jiangsu Hengrui Pharmaceuticals, two of which are in clinical testing.
By Gwendolyn Wu • May 16, 2024 -
Getty Images
5 trends impacting drug spend in the U.S.
Key factors changing how much Americans spend on prescriptions.
By Kelly Bilodeau • May 13, 2024 -
Explore the Trendline➔
Getty Images
TrendlineOncology R&D
Cancer research remains a prime focus for the industry and often leads to pharma’s most impactful breakthroughs.
By PharmaVoice staff -
Getty Images
Sponsored by SmartLabsThinking inside the box: How SmartLabs is transforming laboratories for modern science and accelerating innovation
SmartLabs offers the first integrated platform combining re-configurable lab infrastructure, operations and scientific expertise.
May 13, 2024 -
Permission granted by Daiichi Sankyo
Q&AThe Enhertu effect: Daiichi’s plan to build on the success of its crown jewel
The CEO of Daiichi Sankyo’s American business explains why it could be poised to become a “top 10” cancer company.
By Meagan Parrish • May 10, 2024 -
Jemal Countess via Getty Images
OpinionThe judicial microscope on abortion meds puts FDA and industry in a precarious spot
The recent SCOTUS case involving mifepristone exposes the risk of drug safety determinations by judicial fiat.
By Meg Alexander • May 9, 2024 -
Getty Images
Lilly’s donanemab will face an Alzheimer’s adcomm in June, setting the stage for a Leqembi showdown
The FDA announced a June advisory committee date, potentially introducing a new Alzheimer’s treatment to compete with Eisai and Biogen’s Leqembi.
By Michael Gibney • May 9, 2024 -
Permission granted by AstraZeneca
Q&AAZ oncology chief says AI can help solve cancer’s ‘ZIP code lottery’ as health disparities persist
Partnerships have been key to building the company’s AI capabilities and patient-focused R&D, said AstraZeneca’s head of U.S. oncology.
By Michael Gibney • May 8, 2024 -
Getty Images
Using the body as ‘a bioreactor’ — a regenerative medicine expert on where the field is headed
The director of the University of Pittsburgh’s McGowan Institute for Regenerative Medicine believes the industry is “turning a corner.”
By Alexandra Pecci • May 7, 2024 -
Getty Images
FDA’s new diagnostic rules draw pharma criticism
Tests frequently used in clinical trials will soon be regulated like medical devices — with some exceptions.
By Amy Baxter • May 6, 2024 -
Carsten Koall via Getty Images
Takeover target? Activist investor believes Novavax tech would be in ‘better hands’ with Big Pharma
With its next earnings report looming, pushback from an investor is adding pressure on Novavax to boost performance.
By Meagan Parrish • May 3, 2024 -
Sarah Silbiger via Getty Images
As AI proliferates in pharma, regulators look to catch up in clinical trials
The FDA’s newly launched Center for Clinical Trial Innovation potentially opens the door for more efficient and expanded AI use, but leaves pharmas wanting more guidance.
By Amy Baxter • May 1, 2024 -
Courtesy of Vertex Pharmaceuticals
ProfileNow a biopharma powerhouse, Vertex’s R&D bedrock could deliver tomorrow’s blockbusters
From its landmark CRISPR approval to its potential breakthrough drug for pain, Vertex’s development approach, led by chief scientific officer Dr. David Altshuler, is paying off.
By Michael Gibney • April 30, 2024 -
Getty Images
4 offbeat biotechs making a splash in the life sciences
From resurrecting an extinct species to improving regenerative medicines with plant-based materials, these biotechs are on the leading edge of science.
By Alexandra Pecci • April 30, 2024 -
Drew Angerer via Getty Images
As BMS announces major cuts, its Karuna deal looks poised to drive growth
The company's schizophrenia drug picked up in its $14 billion acquisition of Karuna Therapeutics recently generated positive long-term data from its phase 3 program.
By Kelly Bilodeau • April 29, 2024 -
Courtesy of Alltrna
Q&AHow a biotech exec is leveraging Big Pharma lessons to advance tRNA
Michelle Werner shares how the lessons from her resume — and personal experience — are driving her work with novel therapeutics.
By Amy Baxter • April 29, 2024 -
Permission granted by Ovid Therapeutics
Q&ANeuroscience has entered a new era. Now it’s time for a ‘moonshot’ approach.
Dr. Jeremy Levin, CEO of Ovid Therapeutics, explains how scientific advances have converged to create a new era of drug development potential.
By Meagan Parrish • April 26, 2024 -
Getty Images
Q&AAbbVie and Regenxbio’s ‘multibillion-dollar opportunity’ in vision loss gene therapy
After a successful mid-stage study, the companies aim to upend traditional wet AMD treatments with a one-time gene therapy.
By Amy Baxter • April 24, 2024 -
Mario Tama via Getty Images
Inside J&J’s strategy to de-gender clinical trials
Mark Wildgust, vice president of global medical affairs for J&J's oncology division, shares strategies for making clinical trials gender- and trans-inclusive.
By Alexandra Pecci • April 23, 2024 -
Getty Images
Vistagen’s on-demand nasal spray could provide a novel option for social anxiety
The fast-acting medication is one of a few new approaches being tested for the crippling condition.
By Kelly Bilodeau • April 22, 2024 -
Permission granted by Amylyx Pharmaceuticals
Behind the ‘encouraging’ new results for Amylyx’s beleaguered drug
Where Amylyx ultimately failed in ALS, it could prevail in a rare disease. The doctor leading this research explains why.
By Meagan Parrish • April 19, 2024 -
Getty Images
Roivant spinoff tackles growing complexity of clinical trials
As precision medicine booms, all trials are starting to look like rare disease trials, the company said.
By Kelly Bilodeau • April 18, 2024 -
Sean Gallup via Getty Images
3 patent expirations in 2024 and how companies are pivoting
As the cliffs approach, pharma companies are tackling the sales hit with diverging strategies.
By Amy Baxter • April 17, 2024 -
Chris McGrath via Getty Images
Deep DiveUkraine was pharma’s ‘darling’ of clinical trials. As war drags on, will the industry come back?
New clinical trial starts are picking back up, but are still far below their bustling pre-war level.
By Meagan Parrish • April 16, 2024 -
Permission granted by Ocugen
Biotech SpotlightTraditional gene therapies are uber-niche. Ocugen hopes to change that.
The biotech is developing a ‘gene-agnostic’ approach to expand the patient pool for gene therapies.
By Alexandra Pecci • April 15, 2024 -
Getty Images
Where the GLP-1 weight loss market goes will depend on data
As GLP-1s expand into new disease categories, their impact could be enough to overtake leading cardiovascular drugs.
By Amy Baxter • April 15, 2024
Previous
